APA (7th ed.) Citation

P, H., YL, H., T, P., G, F., N, S., BE, K., & G, F. (2025). Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study. Targeted oncology, 20(5), 833. https://doi.org/10.1007/s11523-025-01174-0

Chicago Style (17th ed.) Citation

P, Hanafin, Ho YL, Papathanasiou T, Fulci G, Sule N, Kremer BE, and Ferron-Brady G. "Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study." Targeted Oncology 20, no. 5 (2025): 833. https://doi.org/10.1007/s11523-025-01174-0.

MLA (9th ed.) Citation

P, Hanafin, et al. "Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study." Targeted Oncology, vol. 20, no. 5, 2025, p. 833, https://doi.org/10.1007/s11523-025-01174-0.